Stem cell-based therapies for HIV/AIDS

Advanced Drug Delivery Reviews

Volumn 103, Issue , 2016, Pages 187-201

  Pernet, Olivier ^a,b   Yadav, Swati Seth ^a,b   An, Dong Sung ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti HIV genes; CRISPR Cas9; Genome editing technologies; Hematopoietic stem progenitor cells; HIV; RNA interference; TALEN; Zinc finger nucleases

Indexed keywords

CYTOLOGY; DISEASES; DRUG THERAPY; GENE THERAPY; GENETIC ENGINEERING;

ANTI-HIV; CRISPR/CAS9; EDITING TECHNOLOGY; PROGENITOR CELL; RNA INTERFERENCE; TALEN; ZINC FINGER NUCLEASE;

STEM CELLS;

ADENOVIRUS VECTOR; ANTI HIV SHORT HAIRPIN RNA; C46 FUSION INHIBITOR; CCR5 CRISPR ASSOCIATED PROTEIN 9; CCR5 RIBOZYME; CCR5 SH1005; CCR5 SHORT HAIRPIN RNA; CCR5 TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; CCR5 ZINC FINGER NUCLEASE; CHEMOKINE RECEPTOR CCR5; CHIMERIC ANTIGEN RECEPTOR; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; CXCR4 CRISPR ASSOCIATED PROTEIN 9; CXCR4 SHORT HAIRPIN RNA; CXCR4 TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; CXCR4 ZINC FINGER NUCLEASE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LENTIVIRUS VECTOR; OLIGONUCLEOTIDE; PLACEBO; PROTEIN KINASE C ACTIVATOR; RIBOZYME; RIBOZYME OZ1; SHORT HAIRPIN RNA; TAR DECOY; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER NUCLEASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SELF-RENEWAL; DNA MODIFICATION; ENGRAFTMENT; GENE THERAPY; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; ANIMAL; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HUMANS;

EID: 84966470292     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.027     Document Type: Review

References (118)

1. [1] Chung, J., Scherer, L.J., Gu, A., Gardner, A.M., Torres-Coronado, M., Epps, E.W. et al., Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMTP140K drug resistance gene. Mol. Ther. 22 (2014), 952–963, 10.1038/mt.2014.32.
2. [2] Sáez-Cirión, A., Pancino, G., HIV controllers: a genetically determined or inducible phenotype?. Immunol. Rev. 254 (2013), 281–294, 10.1111/imr.12076.
3. [3] Deeks, S.G., HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med., 62, 2011, 141, 10.1146/annurev-med-042909-093756.
4. [4] Ramana, K.V., Sabitha, V., Rao, R., A study of alternate biomarkers in HIV disease and evaluating their efficacy in predicting T CD4 + cell counts and disease progression in resource poor settings in highly active antiretroviral therapy (HAART) era. J. Clin. Diagn. Res. 7 (2013), 1332–1335, 10.7860/JCDR/2013/5306.3138.
5. [5] Allers, K., Schneider, T., CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy. Curr. Opin. Virol. 14 (2015), 24–29, 10.1016/j.coviro.2015.06.007.
6. [6] Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K. et al., Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 (2009), 692–698, 10.1056/NEJMoa0802905.
7. [7] Brown, T.R., I am the Berlin patient: a personal reflection. AIDS Res. Hum. Retrovir. 31 (2015), 2–3, 10.1089/aid.2014.0224.
8. [8] Hütter, G., Blüthgen, C., Neumann, M., Reinwald, M., Nowak, D., Klüter, H., Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion. AIDS Res. Ther., 10, 2013, 26, 10.1186/1742-6405-10-26.
9. [9] Persaud, D., Palumbo, P.E., Ziemniak, C., Hughes, M.D., Alvero, C.G., Luzuriaga, K. et al., Dynamics of the resting CD4 + T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS Lond. Engl. 26 (2012), 1483–1490, 10.1097/QAD.0b013e3283553638.
10. [10] Kordelas, L., Verheyen, J., Esser, S., Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 371 (2014), 880–882, 10.1056/NEJMc1405805.
11. [11] Henrich, T.J., Hanhauser, E., Marty, F.M., Sirignano, M.N., Keating, S., Lee, T.-H. et al., Antiretroviral-free HIV-1 remission and viral rebound following allogeneic stem cell transplantation: a report of two cases. Ann. Intern. Med. 161 (2014), 319–327, 10.7326/M14-1027.
12. [12] Kiem, H.-P., Jerome, K.R., Deeks, S.G., McCune, J.M., Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 10 (2012), 137–147, 10.1016/j.stem.2011.12.015.
13. [13] Hütter, G., Bodor, J., Ledger, S., Boyd, M., Millington, M., Tsie, M. et al., CCR5 targeted cell therapy for HIV and prevention of viral escape. Viruses 7 (2015), 4186–4203, 10.3390/v7082816.
14. [14] Glass, W.G., McDermott, D.H., Lim, J.K., Lekhong, S., Yu, S.F., Frank, W.A. et al., CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203 (2006), 35–40, 10.1084/jem.20051970.
15. [15] Hellier, S., Frodsham, A.J., Hennig, B.J.W., Klenerman, P., Knapp, S., Ramaley, P. et al., Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38 (2003), 1468–1476, 10.1016/j.hep.2003.09.027.
16. [16] Promrat, K., McDermott, D.H., Gonzalez, C.M., Kleiner, D.E., Koziol, D.E., Lessie, M. et al., Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124 (2003), 352–360, 10.1053/gast.2003.50061.
17. [17] Wald, O., Pappo, O., Ari, Z.B., Azzaria, E., Wiess, I.D., Gafnovitch, I. et al., The CCR5Δ32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur. J. Immunogenet. 31 (2004), 249–252, 10.1111/j.1365-2370.2004.00482.x.
18. [18] O'Brien, S.J., Nelson, G.W., Human genes that limit AIDS. Nat. Genet. 36 (2004), 565–574, 10.1038/ng1369.
19. [19] Sarver, N., Cantin, E.M., Chang, P.S., Zaia, J.A., Ladne, P.A., Stephens, D.A. et al., Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247 (1990), 1222–1225.
20. [20] Rossi, J.J., June, C.H., Kohn, D.B., Genetic therapies against HIV. Nat. Biotechnol. 25 (2007), 1444–1454, 10.1038/nbt1367.
21. [21] Cagnon, L., Rossi, J.J., Downregulation of the CCR5 β-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev. 10 (2000), 251–261, 10.1089/108729000421439.
22. [22] Li, M.-J., Kim, J., Li, S., Zaia, J., Yee, J.-K., Anderson, J. et al., Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12 (2005), 900–909, 10.1016/j.ymthe.2005.07.524.
23. [23] Michienzi, A., Li, S., Zaia, J.A., Rossi, J.J., A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. 99 (2002), 14047–14052, 10.1073/pnas.212229599.
24. [24] Li, M.-J., Bauer, G., Michienzi, A., Yee, J.-K., Lee, N.-S., Kim, J. et al., Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. 8 (2003), 196–206, 10.1016/S1525-0016(03)00165-5.
25. [25] Kim, D.H., Rossi, J.J., Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8 (2007), 173–184, 10.1038/nrg2006.
26. [26] Qin, X.-F., An, D.S., Chen, I.S.Y., Baltimore, D., Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. 100 (2003), 183–188, 10.1073/pnas.232688199.
27. [27] An, D.S., Qin, F.X.-F., Auyeung, V.C., Mao, S.H., Kung, S.K.P., Baltimore, D. et al., Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther. 14 (2006), 494–504, 10.1016/j.ymthe.2006.05.015.
28. [28] An, D.S., Donahue, R.E., Kamata, M., Poon, B., Metzger, M., Mao, S.-H. et al., Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. 104 (2007), 13110–13115, 10.1073/pnas.0705474104.
29. [29] Liang, M., Kamata, M., Chen, K.N., Pariente, N., An, D.S., Chen, I.S.Y., Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J. Gene Med. 12 (2010), 255–265, 10.1002/jgm.1440.
30. [30] Shimizu, S., Hong, P., Arumugam, B., Pokomo, L., Boyer, J., Koizumi, N. et al., A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115 (2010), 1534–1544, 10.1182/blood-2009-04-215855.
31. [31] Shimizu, S., Ringpis, G.-E., Marsden, M.D., Cortado, R.V., Wilhalme, H.M., Elashoff, D. et al., RNAi-mediated CCR5 knockdown provides HIV-1 resistance to memory T cells in humanized BLT mice. Mol. Ther.–Nucleic Acids, 4, 2015, e227, 10.1038/mtna.2015.3.
32. [32] Ringpis, G.-E.E., Shimizu, S., Arokium, H., Camba-Colón, J., Carroll, M.V., Cortado, R. et al., Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS ONE, 7, 2012, e53492, 10.1371/journal.pone.0053492.
33. [33] Wolstein, O., Boyd, M., Millington, M., Impey, H., Boyer, J., Howe, A. et al., Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol. Ther.–Methods Clin. Dev., 1, 2014, 11, 10.1038/mtm.2013.11.
34. [34] Mani, M., Kandavelou, K., Dy, F.J., Durai, S., Chandrasegaran, S., Design, engineering, and characterization of zinc finger nucleases. Biochem. Biophys. Res. Commun. 335 (2005), 447–457, 10.1016/j.bbrc.2005.07.089.
35. [35] Perez, E.E., Wang, J., Miller, J.C., Jouvenot, Y., Kim, K.A., Liu, O. et al., Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26 (2008), 808–816, 10.1038/nbt1410.
36. [36] Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V. et al., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28 (2010), 839–847, 10.1038/nbt.1663.
37. [37] Saydaminova, K., Ye, X., Wang, H., Richter, M., Ho, M., Chen, H. et al., Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Mol. Ther. Methods Clin. Dev., 1, 2015, 14057, 10.1038/mtm.2014.57.
38. [38] Heyer, W.-D., Ehmsen, K.T., Liu, J., Regulation of homologous recombination in eukaryotes. Annu. Rev. Genet. 44 (2010), 113–139, 10.1146/annurev-genet-051710-150955.
39. [39] Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W.-L. et al., Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol., 2015, 10.1038/nbt.3408.
40. [40] Mock, U., Machowicz, R., Hauber, I., Horn, S., Abramowski, P., Berdien, B. et al., mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res. 43 (2015), 5560–5571, 10.1093/nar/gkv469.
41. [41] Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., Cathomen, T., A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39 (2011), 9283–9293, 10.1093/nar/gkr597.
42. [42] Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E. et al., RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826, 10.1126/science.1232033.
43. [43] Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N. et al., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823, 10.1126/science.1231143.
44. [44] Cho, S.W., Kim, S., Kim, J.M., Kim, J.-S., Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31 (2013), 230–232, 10.1038/nbt.2507.
45. [45] Mandal, P.K., Ferreira, L.M.R., Collins, R., Meissner, T.B., Boutwell, C.L., Friesen, M. et al., Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15 (2014), 643–652, 10.1016/j.stem.2014.10.004.
46. [46] Gaj, T., Gersbach, C.A., Barbas, C.F., ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31 (2013), 397–405, 10.1016/j.tibtech.2013.04.004.
47. [47] Cradick, T.J., Fine, E.J., Antico, C.J., Bao, G., CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res., 41, 2013, 9584, 10.1093/nar/gkt714.
48. [48] Ye, L., Wang, J., Beyer, A.I., Teque, F., Cradick, T.J., Qi, Z. et al., Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9591–9596, 10.1073/pnas.1407473111.
49. [49] Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H.R. et al., Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 12 (2015), 237–243, 10.1038/nmeth.3284.
50. [50] Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J. et al., In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–191, 10.1038/nature14299.
51. [51] Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z. et al., High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529 (2016), 490–495, 10.1038/nature16526.
52. [52] Anderson, J., Banerjea, A., Planelles, V., Akkina, R., Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res. Hum. Retrovir. 19 (2003), 699–706, 10.1089/088922203322280928.
53. [53] Yuan, J., Wang, J., Crain, K., Fearns, C., Kim, K.A., Hua, K.L. et al., Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4 + T cell resistance and enrichment. Mol. Ther. 20 (2012), 849–859, 10.1038/mt.2011.310.
54. [54] Schumann, K., Lin, S., Boyer, E., Simeonov, D.R., Subramaniam, M., Gate, R.E. et al., Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. 112 (2015), 10437–10442, 10.1073/pnas.1512503112.
55. [55] Hou, P., Chen, S., Wang, S., Yu, X., Chen, Y., Jiang, M. et al., Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci. Rep., 5, 2015, 15577, 10.1038/srep15577.
56. [56] Tu, T.C., Nagano, M., Yamashita, T., Hamada, H., Ohneda, K., Kimura, K. et al., A chemokine receptor, CXCR4, which is regulated by hypoxia-inducible factor 2α, is crucial for functional EPC migration to ischemic tissue and wound repair. Stem Cells Dev., 25(3), 2016, 266-276, 10.1089/scd.2015.0290.
57. [57] Lapidot, T., Mechanism of human stem cell migration and repopulation of NOD/SCID and B2m null NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann. N. Y. Acad. Sci. 938 (2001), 83–95.
58. [58] Hildinger, M., Dittmar, M.T., Schult-Dietrich, P., Fehse, B., Schnierle, B.S., Thaler, S. et al., Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 75 (2001), 3038–3042, 10.1128/JVI.75.6.3038-3042.2001.
59. [59] Zahn, R.C., Hermann, F.G., Kim, E.-Y., Rett, M.D., Wolinsky, S.M., Johnson, R.P. et al., Efficient entry inhibition of human and non-human primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther. 15 (2008), 1210–1222, 10.1038/gt.2008.73.
60. [60] Burke, B.P., Levin, B.R., Zhang, J., Sahakyan, A., Boyer, J., Carroll, M.V. et al., Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol. Ther.–Nucleic Acids, 4, 2015, e236, 10.1038/mtna.2015.10.
61. [61] Trobridge, G.D., Wu, R.A., Beard, B.C., Chiu, S.Y., Muñoz, N.M., von Laer, D. et al., Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS ONE, 4, 2009, 10.1371/journal.pone.0007693.
62. [62] van Lunzen, J., Glaunsinger, T., Stahmer, I., von Baehr, V., Baum, C., Schilz, A. et al., Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 15 (2007), 1024–1033, 10.1038/mt.sj.6300124.
63. [63] Hermann, F.G., Egerer, L., Brauer, F., Gerum, C., Schwalbe, H., Dietrich, U. et al., Mutations in gp120 Contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J. Virol. 83 (2009), 4844–4853, 10.1128/JVI.00666-08.
64. [64] Chan, E., Towers, G.J., Qasim, W., Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses 6 (2014), 243–263, 10.3390/v6010243.
65. [65] Neagu, M.R., Ziegler, P., Pertel, T., Strambio-De-Castillia, C., Grütter, C., Martinetti, G. et al., Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119 (2009), 3035–3047, 10.1172/JCI39354.
66. [66] Luban, J., Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 81 (2007), 1054–1061, 10.1128/JVI.01519-06.
67. [67] Yap, M.W., Nisole, S., Stoye, J.P., A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15 (2005), 73–78, 10.1016/j.cub.2004.12.042.
68. [68] Jung, U., Urak, K., Veillette, M., Nepveu-Traversy, M.-É., Pham, Q.T., Hamel, S. et al., Preclinical assessment of mutant human TRIM5α as an anti-HIV-1 transgene. Hum. Gene Ther. 26 (2015), 664–679, 10.1089/hum.2015.059.
69. [69] Sakkhachornphop, S., Barbas, C.F., Keawvichit, R., Wongworapat, K., Tayapiwatana, C., Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration. Hum. Gene Ther. 23 (2012), 932–942, 10.1089/hum.2011.124.
70. [70] Sarkar, I., Hauber, I., Hauber, J., Buchholz, F., HIV-1 proviral DNA excision using an evolved recombinase. Science 316 (2007), 1912–1915, 10.1126/science.1141453.
71. [71] Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski-Rogacz, M., Chakraborty, D. et al., Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat. Biotechnol. 34 (2016), 401–409, 10.1038/nbt.3467.
72. [72] Qu, X., Wang, P., Ding, D., Li, L., Wang, H., Ma, L. et al., Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 41 (2013), 7771–7782, 10.1093/nar/gkt571.
73. [73] Ebina, H., Misawa, N., Kanemura, Y., Koyanagi, Y., Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep., 3, 2013, 2510, 10.1038/srep02510.
74. [74] Ebina, H., Kanemura, Y., Misawa, N., Sakuma, T., Kobayashi, T., Yamamoto, T. et al., A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS ONE, 10, 2015, e0120047, 10.1371/journal.pone.0120047.
75. [75] Wang, G., Zhao, N., Berkhout, B., Das, A.T., CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol. Ther. 24 (2016), 522–526, 10.1038/mt.2016.24.
76. [76] Zhang, Y., Yin, C., Zhang, T., Li, F., Yang, W., Kaminski, R. et al., CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci. Rep., 5, 2015, 10.1038/srep16277.
77. [77] Saayman, S.M., Lazar, D.C., Scott, T.A., Hart, J.R., Takahashi, M., Burnett, J.C. et al., Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol. Ther. 24 (2016), 488–498, 10.1038/mt.2015.202.
78. [78] Limsirichai, P., Gaj, T., Schaffer, D.V., CRISPR-mediated activation of latent HIV-1 expression. Mol. Ther. 24 (2016), 499–507, 10.1038/mt.2015.213.
79. [79] Lee, M.-T.M., Coburn, G.A., McClure, M.O., Cullen, B.R., Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J. Virol., 77, 2003, 11964, 10.1128/JVI.77.22.11964-11972.2003.
80. [80] Strong, C.L., Guerra, H.P., Mathew, K.R., Roy, N., Simpson, L.R., Schiller, M.R., Damaging the integrated HIV proviral DNA with TALENs. PLoS ONE, 10, 2015, e0125652, 10.1371/journal.pone.0125652.
81. [81] Meredith, L.W., Sivakumaran, H., Major, L., Suhrbier, A., Harrich, D., Potent inhibition of HIV-1 replication by a Tat mutant. PLoS ONE, 4, 2009, 10.1371/journal.pone.0007769.
82. [82] ter Brake, O., Konstantinova, P., Ceylan, M., Berkhout, B., Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol. Ther. 14 (2006), 883–892, 10.1016/j.ymthe.2006.07.007.
83. [83] ter ter Brake, O., Hooft, K. ‘t, Liu, Y.P., Centlivre, M., von Eije, K. Jasmijn, Berkhout, B., Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther. 16 (2008), 557–564, 10.1038/sj.mt.6300382.
84. [84] Centlivre, M., Legrand, N., Klamer, S., Liu, Y.P., von Eije, K.J., Bohne, M. et al., Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1. Mol. Ther.–Nucleic Acids, 2, 2013, e120, 10.1038/mtna.2013.48.
85. [85] Herrera-Carrillo, E., Berkhout, B., The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther. 22 (2015), 485–495, 10.1038/gt.2015.11.
86. [86] Anderson, J., Li, M.-J., Palmer, B., Remling, L., Li, S., Yam, P. et al., Safety and efficacy of a lentiviral vector containing three anti-HIV genes—CCR5 ribozyme, Tat-rev siRNA, and TAR Decoy—in SCID-hu mouse-derived T cells. Mol. Ther. 15 (2007), 1182–1188, 10.1038/sj.mt.6300157.
87. [87] DiGiusto, D.L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A. et al., RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med., 2, 2010, 36ra43, 10.1126/scitranslmed.3000931.
88. [88] Walker, J.E., Chen, R.X., McGee, J., Nacey, C., Pollard, R.B., Abedi, M. et al., Generation of an HIV-1-resistant immune system with CD34 + hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J. Virol. 86 (2012), 5719–5729, 10.1128/JVI.06300-11.
89. [89] Didigu, C.A., Wilen, C.B., Wang, J., Duong, J., Secreto, A.J., Danet-Desnoyers, G.A. et al., Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4 + T cells from HIV-1 infection. Blood, 123, 2014, 61, 10.1182/blood-2013-08-521229.
90. [90] Lanao, J.M., Briones, E., Colino, C.I., Recent advances in delivery systems for anti-HIV1 therapy. J. Drug Target. 15 (2007), 21–36, 10.1080/10611860600942178.
91. [91] Miyoshi, H., Smith, K.A., Mosier, D.E., Verma, I.M., Torbett, B.E., Transduction of human CD34 + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283 (1999), 682–686, 10.1126/science.283.5402.682.
92. [92] Reiser, J., Harmison, G., Kluepfel-Stahl, S., Brady, R.O., Karlsson, S., Schubert, M., Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 15266–15271.
93. [94] Mochizuki, H., Schwartz, J.P., Tanaka, K., Brady, R.O., Reiser, J., High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol., 72, 1998, 8873.
94. [95] Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I. et al., Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 (2009), 818–823, 10.1126/science.1171242.
95. [96] Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C. et al., Lentivirus-based gene therapy of hematopoietic stem cells in Wiskott-Aldrich syndrome. Science, 341, 2013, 1233151, 10.1126/science.1233151.
96. [97] Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T. et al., Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 1233158, 10.1126/science.1233158.
97. [98] Tolar, J., Becker, P.S., Clapp, D.W., Hanenberg, H., de Heredia, C.D., Kiem, H.-P. et al., Gene therapy for Fanconi anemia: one step closer to the clinic. Hum. Gene Ther. 23 (2012), 141–144, 10.1089/hum.2011.237.
98. [99] Myburgh, R., Ivic, S., Pepper, M.S., Gers-Huber, G., Li, D., Audigé, A. et al., Lentivector knockdown of CCR5 in hematopoietic stem and progenitor cells confers functional and persistent HIV-1 resistance in humanized mice. J. Virol. 89 (2015), 6761–6772, 10.1128/JVI.00277-15.
99. [100] Shimizu, S., Yadav, S.S., An, D.S., Stable delivery of CCR5-directed shRNA into human primary peripheral blood mononuclear cells and hematopoietic stem/progenitor cells via a lentiviral vector. Shum, K., Rossi, J., (eds.) SiRNA Deliv. Methods, 2016, Springer New York, New York, NY, 235–248 (http://link.springer.com/10.1007/978-1-4939-3112-5_19 (accessed November 12, 2015)).
100. [101] Kong, L.B., Siva, A.C., Rome, L.H., Stewart, P.L., Structure of the vault, a ubiquitous cellular component. Structure 7 (1999), 371–379, 10.1016/S0969-2126(99)80050-1.
101. [102] Champion, C.I., Kickhoefer, V.A., Liu, G., Moniz, R.J., Freed, A.S., Bergmann, L.L. et al., a vault nanoparticle vaccine induces protective mucosal immunity. PLoS ONE, 4, 2009, 10.1371/journal.pone.0005409.
102. [103] Kar, U.K., Srivastava, M.K., Andersson, Å., Baratelli, F., Huang, M., Kickhoefer, V.A. et al., Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS ONE, 6, 2011, e18758, 10.1371/journal.pone.0018758.
103. [104] Shin, J.-Y., Suh, D., Kim, J.M., Choi, H.-G., Kim, J.A., Ko, J.J. et al., Low molecular weight polyethylenimine for efficient transfection of human hematopoietic and umbilical cord blood-derived CD34 + cells. Biochim. Biophys. Acta Gen. Subj. 1725 (2005), 377–384, 10.1016/j.bbagen.2005.05.018.
104. [105] Shayakhmetov, D.M., Papayannopoulou, T., Stamatoyannopoulos, G., Lieber, A., Efficient gene transfer into human CD34 + cells by a retargeted adenovirus vector. J. Virol. 74 (2000), 2567–2583, 10.1128/JVI.74.6.2567-2583.2000.
105. [106] Li, L., Krymskaya, L., Wang, J., Henley, J., Rao, A., Cao, L.-F. et al., Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol. Ther. 21 (2013), 1259–1269, 10.1038/mt.2013.65.
106. [107] Smith, L.J., Ul-Hasan, T., Carvaines, S.K., Van Vliet, K., Yang, E., Wong, K.K. et al., Gene transfer properties and structural modeling of human stem cell-derived AAV. Mol. Ther. 22 (2014), 1625–1634, 10.1038/mt.2014.107.
107. [108] Hofer, U., Henley, J.E., Exline, C.M., Mulhern, O., Lopez, E., Cannon, P.M., Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J. Infect. Dis. 208 (2013), S160–S164, 10.1093/infdis/jit382.
108. [109] Kalomoiris, S., Lawson, J., Chen, R.X., Bauer, G., Nolta, J.A., Anderson, J.S., CD25 preselective anti-HIV vectors for improved HIV gene therapy. Hum. Gene Ther. Methods 23 (2012), 366–375, 10.1089/hgtb.2012.142.
109. [110] Barclay, S.L., Yang, Y., Zhang, S., Fong, R., Barraza, A., Nolta, J.A. et al., Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells. Stem Cells 33 (2015), 870–879, 10.1002/stem.1919.
110. [111] Melkus, M.W., Estes, J.D., Padgett-Thomas, A., Gatlin, J., Denton, P.W., Othieno, F.A. et al., Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12 (2006), 1316–1322, 10.1038/nm1431.
111. [112] Zhen, A., Kamata, M., Rezek, V., Rick, J., Levin, B., Kasparian, S. et al., HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol. Ther. 23 (2015), 1358–1367, 10.1038/mt.2015.102.
112. [113] Kim, S., Kim, N., Presson, A.P., Metzger, M.E., Bonifacino, A.C., Sehl, M. et al., Dynamics of HSPC repopulation in nonhuman primates revealed by a decade-long clonal-tracking study. Cell Stem Cell 14 (2014), 473–485, 10.1016/j.stem.2013.12.012.
113. [114] Younan, P.M., Polacino, P., Kowalski, J.P., Peterson, C.W., Maurice, N.J., Williams, N.P. et al., Positive selection of mC46-expressing CD4 + T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122 (2013), 179–187, 10.1182/blood-2013-01-482224.
114. [115] Younan, P.M., Peterson, C.W., Polacino, P., Kowalski, J.P., Obenza, W., Miller, H.W. et al., Lentivirus-mediated gene transfer in hematopoietic stem cells is impaired in SHIV-infected, ART-treated nonhuman primates. Mol. Ther. J. Am. Soc. Gene Ther. 23 (2015), 943–951, 10.1038/mt.2015.19.
115. [116] Bauer, G., Selander, D., Engel, B., Carbonaro, D., Csik, S., Rawlings, S. et al., Gene therapy for pediatric AIDS. Ann. N. Y. Acad. Sci. 918 (2000), 318–329, 10.1111/j.1749-6632.2000.tb05501.x.
116. [117] Mitsuyasu, R.T., Merigan, T.C., Carr, A., Zack, J.A., Winters, M.A., Workman, C. et al., Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 + cells. Nat. Med. 15 (2009), 285–292, 10.1038/nm.1932.
117. [118] Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G. et al., Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370 (2014), 901–910, 10.1056/NEJMoa1300662.
118. [119] Kohn, D.B., Bauer, G., Rice, C.R., Rothschild, J.C., Carbonaro, D.A., Valdez, P. et al., A clinical trial of retroviral-mediated transfer of AREV-responsive element decoy gene into CD34 + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94 (1999), 368–371.